510 related articles for article (PubMed ID: 1698710)
1. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
3. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
4. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
5. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
6. The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase.
Schönermark S; Filsinger S; Berger B; Hänsch GM
Immunology; 1988 Apr; 63(4):585-90. PubMed ID: 3366469
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins.
Rosenfeld SI; Packman CH; Leddy JP
J Clin Invest; 1983 Apr; 71(4):795-808. PubMed ID: 6403580
[TBL] [Abstract][Full Text] [Related]
8. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.
Farkas I; Baranyi L; Ishikawa Y; Okada N; Bohata C; Budai D; Fukuda A; Imai M; Okada H
J Physiol; 2002 Mar; 539(Pt 2):537-45. PubMed ID: 11882685
[TBL] [Abstract][Full Text] [Related]
9. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells.
Hakulinen J; Meri S
Lab Invest; 1994 Dec; 71(6):820-7. PubMed ID: 7528832
[TBL] [Abstract][Full Text] [Related]
10. Binding of human and rat CD59 to the terminal complement complexes.
Lehto T; Morgan BP; Meri S
Immunology; 1997 Jan; 90(1):121-8. PubMed ID: 9038722
[TBL] [Abstract][Full Text] [Related]
11. Homologous restriction factor: effect on complement C8 and C9 uptake and lysis.
Zalman LS; Müller-Eberhard H
Mol Immunol; 1994 Mar; 31(4):301-5. PubMed ID: 8139583
[TBL] [Abstract][Full Text] [Related]
12. On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes.
Hammer CH; Shin ML; Abramovitz AS; Mayer MM
J Immunol; 1977 Jul; 119(1):1-8. PubMed ID: 559700
[TBL] [Abstract][Full Text] [Related]
13. Target deletion of complement component 9 attenuates antibody-mediated hemolysis and lipopolysaccharide (LPS)-induced acute shock in mice.
Fu X; Ju J; Lin Z; Xiao W; Li X; Zhuang B; Zhang T; Ma X; Li X; Ma C; Su W; Wang Y; Qin X; Liang S
Sci Rep; 2016 Jul; 6():30239. PubMed ID: 27444648
[TBL] [Abstract][Full Text] [Related]
14. Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59.
Hamilton KK; Ji Z; Rollins S; Stewart BH; Sims PJ
Blood; 1990 Dec; 76(12):2572-7. PubMed ID: 1702330
[TBL] [Abstract][Full Text] [Related]
15. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
[TBL] [Abstract][Full Text] [Related]
16. Calcium-loaded erythrocytes have a defect in complement regulation distinct from that resulting from exposure to 2-aminoethylisothiouronium bromide.
Test ST; Mitsuyoshi J
Blood; 1995 Oct; 86(7):2799-806. PubMed ID: 7545473
[TBL] [Abstract][Full Text] [Related]
17. Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis.
Meri S; Morgan BP; Wing M; Jones J; Davies A; Podack E; Lachmann PJ
J Exp Med; 1990 Jul; 172(1):367-70. PubMed ID: 1694224
[TBL] [Abstract][Full Text] [Related]
18. Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: effect of C9 on C5b-8 mediated cell lysis.
Morgan BP; Imagawa DK; Dankert JR; Ramm LE
J Immunol; 1986 May; 136(9):3402-6. PubMed ID: 3514758
[TBL] [Abstract][Full Text] [Related]
19. Restriction of cell lysis by homologous complement: II. Protection of erythrocytes against lysis by newly activated complement.
Houle JJ; Hoffmann EM; Esser AF
Blood; 1988 Feb; 71(2):287-92. PubMed ID: 3337897
[TBL] [Abstract][Full Text] [Related]
20. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
Bhakdi S; Tranum-Jensen J
J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
